Sort
30,917 grants matching “tumor microenvironment”
Optimizing TCR-CD3 signaling for immunotherapy of cancer
$652,880Michelle Krogsgaard · New York University School Of Medicine · R01 · FY2024 · CA
Local microbiota signatures of pro-tumor immunity and checkpoint inhibition susceptibility in lung cancer
$652,880Leopoldo Nicolas Segal · New York University School Of Medicine · R37 · FY2025 · CA
Lung Macrophage Memory Development and Responses in Secondary Pneumonia and Sepsis
$652,872Bibhuti Bhusan Mishra · University Of Texas Hlth Science Center · R01 · FY2023 · AI
Lung Macrophage Memory Development and Responses in Secondary Pneumonia and Sepsis
$652,872Bibhuti Bhusan Mishra · University Of Texas Hlth Science Center · R01 · FY2024 · AI
Bioactivity of CAR T cells secreting T cell engager-anitbodies in humans with glioblastoma
$652,851Marcela Valderrama Maus · Massachusetts General Hospital · R01 · FY2025 · CA
Local microbiota signatures of pro-tumor immunity and checkpoint inhibition susceptibility in lung cancer
$652,794Leopoldo Nicolas Segal · New York University School Of Medicine · R37 · FY2022 · CA
Applying Optical Approaches to the Drug Delivery Problem
$652,784Martin Schnermann · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Sideport Needle Array Technologies for Prioritizing Drugs for Cancer Patients
$652,762James M Olson · Presage Biosciences, Inc. · R42 · FY2012 · CA
Development of First-in-Class RIPK1 Degraders to Improve Cancer Immunotherapies
$652,762Jin Wang · Baylor College Of Medicine · R01 · FY2022 · CA
Bioactivity of CAR T cells secreting T cell engager-anitbodies in humans with glioblastoma
$652,725Marcela Valderrama Maus · Massachusetts General Hospital · R01 · FY2024 · CA
Co-Clinical Research Resource for Imaging Tumor Associated Macrophages
$652,560Heike Elizabeth Daldrup-Link · Stanford University · U24 · FY2021 · CA
Co-Clinical Research Resource for Imaging Tumor Associated Macrophages
$652,473Heike Elizabeth Daldrup-Link · Stanford University · U24 · FY2025 · CA
Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9b in Patients with Prostate Cancer
$652,414Nupam P Mahajan · Washington University · R01 · FY2024 · CA
Project 1: Systematic discovery of cell-intrinsic mechanisms of cancer drug resistance
$652,398Scott R Manalis · Massachusetts Institute Of Technology · U54 · FY2021 · CA
Single Cell Analysis of the Infiltrative Margins of Glioblastoma and Post Treatment Recurrence
$652,348Jeffrey N Bruce · Columbia University Health Sciences · R01 · FY2023 · NS
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
$652,287Daniel J. Powell · University Of Pennsylvania · R01 · FY2023 · CA
Mechanisms of Prostate Tumorigenesis Using Genetically Engineered Mouse Models
$652,207Terry Van Dyke · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
Sustaining antitumor effector CD8+ T cells for cancer therapy
$652,206Bin Zhang · Northwestern University At Chicago · R01 · FY2025 · CA
The impact of interstitial fluid flow on CAR T cell trafficking, distribution, and efficacy
$652,200Jennifer M Munson · Virginia Polytechnic Inst And St Univ · R01 · FY2025 · NS
Host immature myeloid cells in tumor suppressor or promoter roles of TGFbeta
$652,139Li Yang · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
Modulation of Epigenetic Target in the Bone to Treat Breast Cancer Metastasis
$652,042Han Xiao · Rice University · R01 · FY2025 · CA
MR-Guided Focused Ultrasound Combined with Immunotherapy to Treat Malignant Brain Tumors
$652,022Max Wintermark · Stanford University · R01 · FY2017 · CA
Quantitative control of CAR T cells via image-guided delivery and monitoring
$651,868Daniel J. Powell · University Of Pennsylvania · R01 · FY2018 · EB
Quantitative control of CAR T cells via image-guided delivery and monitoring
$651,868Daniel J. Powell · University Of Pennsylvania · R01 · FY2019 · EB
Quantitative control of CAR T cells via image-guided delivery and monitoring
$651,868Daniel J. Powell · University Of Pennsylvania · R01 · FY2020 · EB